Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells from your own tumor could fight cervical cancer

NCT ID NCT06241781

Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called GT101, which uses immune cells taken from a patient's own tumor to fight recurrent or metastatic cervical cancer. About 83 adults will receive either GT101 or a standard chemotherapy drug. The goal is to see if the cell therapy can delay cancer growth better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 83 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) ,must have the ability to understand the requirements of the study); * 2\. The patient must be 18 to 70 years of age at the time of consent; * 3\. Must have a confirmed diagnosis of malignancy of their receptive histologies or cytology: unresectable recurrent or metastatic cervical carcinomas and previously received≥ 1 prior systemic therapy; * 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; * 5\. Expected survival time of ≥ 12 weeks; * 6\. Adequate normal organ and marrow function; * 7\. Before tumor resection, the confirmatory imaging of disease progress since last treatment should be documented. * 8.Patients must have measurable disease measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (in addition to the resected lesion). Exclusion Criteria: * 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring painkiller must already have had a stable pain management options at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry; * 2.Patients who have psychiatric disorders, alcohol, drug or substance abuse; * 3.Women who are pregnant or breastfeeding, or planning to become pregnant within 1 year after cell infusion; * 4.Participate in other clinical trials within 4 weeks prior to screening, or planning to participate in this study and other clinical trials at the same time; * 5.Any other conditions that would make the patient unsuitable candidate for the study at the discretion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Zhongshan Hospital Dalian University

    RECRUITING

    Dalian, Liaoning, 116001, China

  • Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518172, China

  • Dalian Medical University First Affiliated Hospital

    RECRUITING

    Dalian, Liaoning, 116001, China

  • Fudan University Affiliated Obstetrics and Gynecology Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 214432, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

  • Guangxi Medical University Affiliated Cancer Hospital

    RECRUITING

    Guilin, Guangxi, 530021, China

  • Harbin Medical University Affiliated Cancer Hospital

    RECRUITING

    Ha’erbin, Heilongjjiang, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450003, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430079, China

  • Jiangxi Maternal and Child Health Hospital

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • Jining First People's Hospital

    RECRUITING

    Jining, Shandong, 272002, China

  • Shandong First Medical University Affiliated Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, 030013, China

  • Sichuan University West China Second Hospital

    RECRUITING

    Chengdu, Sichuan, 610044, China

  • Southeast University Affiliated Zhongda Hospital

    RECRUITING

    Nanjing, Jiangsu, 210009, China

  • The Fifth Medical Center of the General Hospital of the People's Liberation Army of China

    RECRUITING

    Beijing, Beijing Municipality, 222002, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 450052, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, 710061, China

  • Tianjin Cancer Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300181, China

  • Xiangya Second Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410012, China

  • Yibin Second People's Hospital

    RECRUITING

    Yibin, Sichuan, 644002, China

  • Yun Cancer Hospital

    RECRUITING

    Kunming, Yunnan, 650118, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.